DK1287142T3 - Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens - Google Patents
Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvensInfo
- Publication number
- DK1287142T3 DK1287142T3 DK01936423T DK01936423T DK1287142T3 DK 1287142 T3 DK1287142 T3 DK 1287142T3 DK 01936423 T DK01936423 T DK 01936423T DK 01936423 T DK01936423 T DK 01936423T DK 1287142 T3 DK1287142 T3 DK 1287142T3
- Authority
- DK
- Denmark
- Prior art keywords
- neuropeptide
- nucleic acid
- sdf
- acid molecule
- acid sequence
- Prior art date
Links
- 102000003797 Neuropeptides Human genes 0.000 title abstract 7
- 108090000189 Neuropeptides Proteins 0.000 title abstract 7
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 102000019034 Chemokines Human genes 0.000 title abstract 3
- 108010012236 Chemokines Proteins 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title abstract 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10027383A DE10027383A1 (de) | 2000-06-02 | 2000-06-02 | Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1287142T3 true DK1287142T3 (da) | 2006-03-13 |
Family
ID=7644466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01936423T DK1287142T3 (da) | 2000-06-02 | 2001-06-01 | Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030215792A1 (https=) |
| EP (1) | EP1287142B1 (https=) |
| JP (1) | JP2004521607A (https=) |
| AT (1) | ATE309361T1 (https=) |
| AU (1) | AU6233501A (https=) |
| DE (2) | DE10027383A1 (https=) |
| DK (1) | DK1287142T3 (https=) |
| ES (1) | ES2251483T3 (https=) |
| WO (1) | WO2001092530A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7358044B2 (en) * | 2003-04-16 | 2008-04-15 | Argyll Biotechnologies, Llc. | Prophylactic and therapeutic benefits of a new class of immune stimulating peptides |
| US7776564B2 (en) | 2004-04-30 | 2010-08-17 | Five Prime Therapeutics, Inc. | Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| BRPI0617823A2 (pt) * | 2005-10-31 | 2011-08-09 | Laboratoires Serono Sa | uso de sdf-1 para o tratamento e/ou prevenção de doenças neurológicas e composição farmacêutica |
| JP2009532057A (ja) * | 2006-04-07 | 2009-09-10 | ニューロ セラピューティクス エービー | 神経細胞の生存および発生 |
| EP2049146A2 (en) * | 2006-07-07 | 2009-04-22 | Hans-Werner Müller | Use of proteins of the sdf-1-family for for improvement of axonal plasticity or for axonal regeneration following lesions |
| US7696309B2 (en) * | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US20110034383A1 (en) * | 2007-10-15 | 2011-02-10 | Institut Pasteur | Cxcl12 gamma a chemokine and uses thereof |
| US9308277B2 (en) | 2010-02-25 | 2016-04-12 | Mesoblast International Sàrl | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| WO2012170495A1 (en) | 2011-06-07 | 2012-12-13 | Provasculon, Inc. | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| JP3367581B2 (ja) * | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6114502A (en) * | 1996-04-10 | 2000-09-05 | Axys Pharmaceuticals, Inc. | Gene family associated with neurosensory defects |
| AU2450797A (en) * | 1996-04-10 | 1997-10-29 | Axys Pharmaceuticals, Inc. | Gene family associated with neurosensory defects |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| MXPA00003885A (es) * | 1997-10-22 | 2004-04-23 | Inst Genetics Llc | Quimiocinas con modificiaciones de la terminacion amino. |
| US6747137B1 (en) * | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| AU3773099A (en) * | 1998-04-29 | 1999-11-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Identification of polymorphisms in the pctg4 region of xq13 |
| AU5134799A (en) * | 1998-07-30 | 2000-02-21 | Human Genome Sciences, Inc. | 98 human secreted proteins |
| CA2391814A1 (en) * | 1999-12-16 | 2001-06-21 | Ribotargets Limited | Assays |
-
2000
- 2000-06-02 DE DE10027383A patent/DE10027383A1/de not_active Ceased
-
2001
- 2001-06-01 JP JP2002500722A patent/JP2004521607A/ja active Pending
- 2001-06-01 ES ES01936423T patent/ES2251483T3/es not_active Expired - Lifetime
- 2001-06-01 AT AT01936423T patent/ATE309361T1/de not_active IP Right Cessation
- 2001-06-01 EP EP01936423A patent/EP1287142B1/de not_active Expired - Lifetime
- 2001-06-01 WO PCT/EP2001/006250 patent/WO2001092530A1/de not_active Ceased
- 2001-06-01 DK DK01936423T patent/DK1287142T3/da active
- 2001-06-01 AU AU62335/01A patent/AU6233501A/en not_active Abandoned
- 2001-06-01 DE DE50108009T patent/DE50108009D1/de not_active Expired - Lifetime
-
2002
- 2002-12-02 US US10/308,322 patent/US20030215792A1/en not_active Abandoned
-
2008
- 2008-01-22 US US12/010,221 patent/US20080319165A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE50108009D1 (de) | 2005-12-15 |
| ATE309361T1 (de) | 2005-11-15 |
| US20080319165A1 (en) | 2008-12-25 |
| WO2001092530A1 (de) | 2001-12-06 |
| AU6233501A (en) | 2001-12-11 |
| JP2004521607A (ja) | 2004-07-22 |
| EP1287142B1 (de) | 2005-11-09 |
| ES2251483T3 (es) | 2006-05-01 |
| US20030215792A1 (en) | 2003-11-20 |
| DE10027383A1 (de) | 2001-12-20 |
| EP1287142A1 (de) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
| NO963371L (no) | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| BRPI0315666B8 (pt) | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| DK1287142T3 (da) | Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens | |
| HUP9903921A2 (hu) | Tumor nekrózis faktorral rokon ligandum | |
| DK208987D0 (da) | Polypeptider og antistoffer, som er karakteristiske for papillomvirus, og deres anvendelse ved diagnostiske metoder og i vacciner | |
| EP4549947A2 (en) | Reducing the risk of major adverse cardiac events | |
| SE9602496D0 (sv) | Method and means for producing a fibrinogen binding protein and its use in biotechnology | |
| EP0832233A4 (en) | Human chemokine beta-13 | |
| MY141459A (en) | Recombinant anti-idiotypic antibodies | |
| DK0932689T3 (da) | Assay for homocystein og homocysteindesulphurase fra protozo-trichomonas vaginalis | |
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
| DE60125537D1 (de) | Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen | |
| DE60118359D1 (de) | Humanische pellino-polypeptide | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| AP2000001917A0 (en) | Gene encoding labyrinthin, a marker for cancer. | |
| Michiels et al. | Carcinoma cell‐derived chemokines and their presence in oral fluid | |
| AR004567A1 (es) | Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi. | |
| AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
| NO993653L (no) | FremgangsmÕte for diagnose, prognose og behandling av glaukom og relaterte sykdommer | |
| ES2121754T3 (es) | Fragmento de adnc que codifica el gen del receptor del interferon alfa y procedimiento para la preparacion de una proteina correspondiente. | |
| EP1036164A4 (en) | CHEMOKINE ALPHA-5 (CK $ g (a) -5) |